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Abstract
The authors present the review of factors influencing epidemiological situation of tuberculosis in Poland and in the world. The 
groups of increased risk of tuberculosis, and clinical conditions predisposing to activation of latent tuberculosis infection (LTBI) 
such as HIV, uremia, diabetes mellitus, transplantation of organs, treatment with glucocorticosteroids and with antibodies to TNF 
and to its receptors, were presented. The higher prevalence and worse prognosis of tuberculosis in elderly people was empha-
sised. The methods of LTBI recognition, according to recent recommendations, with special consideration to patients in immu-
nosupression, were shown. Methods of treatment to prevent LTBI activation, according to WHO experts, were also presented. 
All data were discussed in relation to the actual epidemiological situation of tuberculosis in Poland.
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Introduction
Tuberculosis (TB) is still one of the most 
common infectious diseases worldwide. One 
third of the world population is infected with 
tubercle bacilli. According to epidemiological 
estimations, in 2014, 9.6 million of people were 
diagnosed with TB worldwide and 1.5 milion of 
patients died of this disease [1].
The epidemiological situation of TB is dif-
ferent in various parts of the world. In 2014, the 
highest estimated tuberculosis incidence rates 
were noted in South-East Asia (211/100 000) 
and in Africa (281/100 000) — in Lesotho, South 
Africa and Swaziland, an estimated incidence 
reached 1000/100 000. The lowest incidence rates 
were noted in North America (3.1/100 000 — in 
the US and 5.2/100 000 in Canada) [1]. The coun-
tries with TB incidence rate below 10/100 000 are 
approaching the elimination phase of the disease. 
In 2013, there were 18 such countries in the Eu-
ropean Union and European Economic Area [2]. 
In Poland - a great improvement of epidemio-
logical situation of TB has been achieved over 
the past 60 years, illustrated by the decrease in 
notification rate from 290.4/100 000 in 1957 to 
17.4/100 000 in 2014 [3]. According to the ECDC 
criteria, Poland is already the low-incidence co-
untry. However, the incidence of TB in Poland 
is still higher than the average for the European 
Union (12.7/100 000 in 2013) [2]. 
In the countries with a low incidence of TB, 
a higher prevalence of disease in certain risk 
groups is observed. Groups at increased risk of 
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TB include imigrants from the countries with 
high prevalence of tuberculosis, poor people, 
prisoners, homeless persons, alcohol abusers, 
drug addicts and individuals infected with human 
immunodeficiency virus (HIV). These vulnerable 
and hard-to-reach groups require the special care 
[4]. Epidemiological phenomena observed in the 
low-incidence countries are also found in Poland. 
The Polish group of patients with TB includes 
a larger proportion of unemployed and homeless 
people, compared to the entire population [5, 6]. 
Despite lowering of incidence rate of TB in 
Poland, mortality rate (calculated on the basis of 
death certificates), was 1.4/100 000 in 2013, the-
refore it was nearly twice as high as the average in 
the European Union [2, 3]. One of the reasons of 
such finding, may be the delay in the recognition 
of the disease. In one of the greatest centers for 
tuberculosis treatment in Poland, Otwock, spu-
tum positive patients had been symptomatic for 
3−6 months, before tuberculosis was recognised. 
In addition, in 80% of newly admitted patients, 
the advanced disease was recognised, with chest 
X-ray lesions exceeding three lung fields [7, 8]. 
Nevertheless, the same situation was described in 
other countries. In the US, a great decline of regi-
stered TB cases occured in the years 1993–2006. 
At the same time, the proportion of patients with 
advanced pulmonary tuberculosis increased from 
18.5% to 26.1% [9]. The increased prevalence 
of advanced TB was even more pronounced in 
populations not regarded as being at risk of this 
disease, in white people, and in those born in 
the US [9].
The other reason for relatively high TB-re-
lated mortality in Poland may be attributed to 
the low proportion of patients with positive tre-
atment results. In 2013, the success of treatment 
has been achieved only in 58.2% of patients 
with culture confirmed pulmonary tuberculosis. 
2.6% of culture positive patients died of TB and 
7.1% defaulted their treatment. In addition, no 
information concerning the fate of 20% of sputum 
positive patients was obtained [3].
This poor adherance to treatment in some 
populations of Polish patients was probably cau-
sed by poor social conditions, unemployment, 
alcoholism, low education, and not rarely — ho-
melessness [5, 6, 10, 11]. The same causes for 
inadequate treatment results were also observed 
in other countries [4, 12].
Nevertheless, this situation indicates that the 
problem of tuberculosis in Poland is not solved, 
and that it may be useful to remind various medi-
cal conditions increasing the risk of tuberculosis. 
According to international standards, knowledge 
about TB risk factors is essential for proper and 
immediate diagnosis of tuberculosis [13]. 
Factors influencing susceptibility to TB infection
It is known that infection with tubercle ba-
cilli most often spreads by inhalation of little air 
droplets containing the microbes. Their source is 
usually a person with cavitary tuberculosis of the 
lung. TB bacilli very often penetrate the respira-
tory system without causing any infection. The 
susceptibility to infection and to development 
of active disease may depend, among others, 
on the age of the exposed person, the genetic 
backgrounds, social status, eventual addictions, 
coexisiting diseases, and their treatment [14−19].
There are several very rare genetic abnorma-
lities called „Mendelian susceptibility to mycobac-
terial diseases” combined mainly with mutations 
of receptors to interferon gamma (IFN gamma) 
and interleukin 12 (IL 12). Such patients are very 
prone to develop disseminated disease, not only 
after the contact with tubercle bacilli but also 
with nontuberculous mycobacteria and sometimes 
even after BCG vaccination. They are also very 
sensitive to the infection with Salmonella sp. and 
with other intracellular bacteria and fungi [14].
More often however, the diversity of host 
genetic factors is caused by different ethnicity of 
the population, and this phenomenon is respon-
sible for different rates of infection and disease 
in different ethnic groups [15−17].
Other factors influencing the infection rate 
after exposition are as follows: the density of in-
fected air droplets in the atmosphere, the duration 
of exposition and the degree of virulence of the 
particular species of tubercle bacilli [15]. One of 
them, identified by van Soolingen in China, was 
called Beijing [20]. The Beijing strain is more 
virulent in vitro and in experimental animals com-
paring to other TB genotypes [21]. It has also the 
increased ability to become drug resistant [21]. In 
addition, it can modulate immune response of the 
host [22]. Beijing strains constitute 13% of phe-
notypes identified worldwide. They were most 
prevalent in Asia, but have been also found in 
many other parts of the world, and were respon-
sible for local epidemics [23]. In Poland, Beijing 
strains were identified by spoligotyping in 6.5% 
of isolates obtained between 2007 and 2011 [24]. 
The percentage of drug resistant strains was 
higher among Beijing comparing to non-Beijing 
strains (MDR 38% vs 5.8%, and XDR — 4% vs 
1.4%, respectively) [24].
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Latent tuberculosis infection
In about 95% of infected persons, tubercle 
bacilli persist in the organism, but do not prolife-
rate (or proliferate only occasionally), and do not 
cause the development of disease. Such a clinical 
situation was called latent tuberculosis infection 
(LTBI). LTBI protects to some extent against TB 
reinfection, which is especially important in the 
countries with high TB prevalence. 
However, the equilibrium of LTBI can be 
disturbed by advanced age, poor conditions of 
life (malnutrition), addictions (alcohol, narcotics, 
cigarettes), silicosis, other diseases (HIV, diabetes, 
renal insufficiency, neoplasms of hematopoietic 
system) or their treatment (anti-TNF, immunosup-
presive treatment, glucocorticoisteroids or others).
LTBI can be recognised by tests based on 
the ability of the sensitized memory lymphocy-
tes and other cells to recognise the antigens of 
M. tuberculosis. Tuberculin skin test (TST) is 
based on measuring of induration caused by 
subcutaneous reaction of immunocompetent cells 
with the antigens included in tuberculin. Tuber-
culin used in TST include antigens of M. tuber-
culosis but also antigens of BCG and non-tuber-
culous mycobacteria. Thus the reaction may be 
falsely positive in the patients who received BCG 
vacination or in those infected with non-tuber-
culous mycobacteria. More specific tests (IGRAs) 
are based on measuring the amount of IFN gamma 
released after exposition of mononuclear cells to 
M. tuberculosis antigens (Quantiferon-Tb Gold) or 
by counting cells which produce IFN gamma after 
such exposition (T.SPOT.Tb). IGRAs are more 
specific than TST because they are based on re-
cognition of antigens specific for M. tuberculosis. 
In addition, IGRAs are more sensitive than TST 
in the state of immunosupression. Nevertheless, 
in profound immunosupression both tests can be 
negative. On the other hand, the positive test re-
sult, does not differentiate between the infection 
and active disease [25].
Diseases responsible for activation of LTBI
HIV
One of the most important risk factors for 
activation of LTBI and the development of active 
disease is HIV infection. Tubercle bacilli and HIV 
are reciprocally synergistic. HIV drives suscepti-
bility to infection with tubercle bacilli and pro-
gression to active tuberculosis but also tubercle 
bacilli promote HIV replication [26].
Most cases of HIV infection are noted in 
south Africa, Asia, Latin America and Eastern 
Europe, but infection is diagnosed worldwide 
[26]. Globally, the estimated number of tuberculo-
sis combined with HIV infection was 1.2 mln in 
2014 [1]. In Poland in 2013, only 1097 cases of 
HIV and 151 of AIDS were diagnosed, and 123 
deaths in the course od AIDS were identified [27]. 
Tuberculosis was AIDS indicator disease in 35 of 
the registered cases [28].
The risk of developing active tuberculosis is 
about 20 times greater in the HIV infected person 
than in others [26]. The susceptibility depends 
on the degree of immunosuppresion, measured by 
number of CD4 T lymphocytes in the peripheral 
blood. If it is lower than 200 cells/ml, tuberculosis 
presents with disseminated lesions and extrapul-
monary localisations, but less cavities. TST is 
usually negative [26].
The situation has changed after the introduc-
tion of highly active antiretoviral treatment (HA-
ART). The frequency of tuberculosis decreased, 
nevertheless, it still occures about five times more 
frequently than in patients not coinfected with 
HIV [29]. Treatment with HAART creates however 
another problems. There is some interaction be-
tween those drugs and rifampicin, and in addition, 
there is a risk of development of immune recon-
stitution inflammatory syndrome (IRIS) [30, 31].
IRIS manifests itself by the sudden pro-
gression of already treated tuberculosis (para-
doxical tuberculosis-associated IRIS) or by the 
appearance of tuberculosis not diagnosed before 
(unmasking tuberculosis-associated IRIS). The 
development and course of tuberculosis in such a 
case is usually very abrupt, and may be the cause 
of death of the patient [26, 30, 31].
It is presumed that this syndrome is depen-
dent on too great, too quick and unbalanced rege-
neration of the immunologic system after reduc-
tion of the virus load in the course of HAART and 
excessive response to M. tuberculosis antigens. 
This may be confirmed by the presence of various 
cytokines in patients’ blood and usually a good 
effect of treatment with glucocorticosteroids [32].
There were many debates concerning the 
time of HAART introduction in persons already 
treated for tuberculosis. IRIS develops more 
frequently and has more severe consequences if 
HAART is introduced early. On the other hand, 
patients in whom introduction of HAART is deta-
ined, more often die from tuberculosis. Therefore, 
current standards of TB care propose to introdu-
ce HAART early, after 2, but not later than after 
8 weeks of antituberculous treatment [13, 33].
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TB remains a great health care problem 
when combined with HIV infection. The diffi-
culties concerning treatment of these conditions 
have been illustrated by the paper published by 
Marcy et al. [34]. The authors describe the group 
of 661 patients in the state of deep immunosu-
pression (CD4 T count was lower than 200/ml), 
treated with HAART and antituberculous drugs. 
149 patients died in the course of treatment and in 
28.2% — the cause of death was tuberculosis [34]. 
The number of deaths from tuberculosis in 
HIV infected persons depends on local epidemio-
logy. Podlekareva et al. had proved that as many 
as 48.5% of HIV positive patients from Eastern 
Europe died from tuberculosis [35]. In Western 
Europe the number of deaths from tuberculosis at 
the same time was only 18.5% [35]. In the report 
of Lucejko et al., during the prolonged observa-
tion of 389 patients with HIV infection in Poland, 
tuberculosis was diagnosed in 41 (10%). 15% of 
them died of tuberculosis [36]. 
Globally in 2014, 390,000 deaths from TB in 
HIV infected patients occurred [1]. The increased 
death rate from tuberculosis in HIV depends 
to some extent on its delayed recognition. Dia-
gnosing tuberculosis in immunosupression is 
difficult, thus it is important to take into acount 
the spectrum of symptoms. In the case of cough, 
elevated temperature and sweating, it is reaso-
nable to perform sputum, and eventually BAL 
culture for tuberculous bacilli, even if chest x-ray 
is inconclusive [37]. Because persons with HIV 
infection and pulmonary tuberculosis frequently 
have negative sputum smears, rapid molecular 
tests directed at the recognition of TB such as 
Xpert MTB/RIF, should be performed in such 
patients as the initial diagnostic test. Xpert MTB/
RIF increases the chance of recognising TB in this 
group of patients. The overall sensitivity of this 
method in HIV infected population with TB was 
79% (61% — for persons with smear-negative, 
culture positive TB and 97% — for smear-positi-
ve specimens) and the specificity was 98% [13].
End stage renal disease with uremia
There are profound alterations in immune re-
sponses associated with uremia and exacerbated 
by dialysis [38]. Those changes were associated 
with impaired activation of T lymphocytes [39] 
and macrophages [40]. Incidence of active tu-
berculosis in the patients treated with long-term 
dialysis is 6.9–52.5 higher than in the general 
population of the same region. The additional risk 
factors in this group of patients are the following: 
advanced age, diabetes mellitus, the presence of 
fibrotic lesions on chest X-ray and the period of 
dialysis exceeding 12 months [38]. In addition, 
the effect of antituberculous therapy is worse in 
this group than in controls without uremia. They 
significantly more often develop drug induced 
hepatitis and die during treatment [41].
Diabetes mellitus (DM)
The link between DM and tuberculosis has 
been recognised for centuries. It is known that 
TB occurs 3 times more often in patients with 
DM than in others [42, 43]. The risk is greater if 
DM is not well controlled. Hyperglycemia and 
the deficit of insulin production have harmful 
effects on lymphocytes and macrophages. Thus 
some immunosuppression linked with DM is 
observed [44] and the delay in diagnosis is noted 
[45]. This is probably the cause of more advan-
ced pulmonary disease presenting with cavities 
in newly recognised patients with tuberculosis 
and DM, comparing to those without DM [42, 
46]. DM is not only an important risk factor for 
tuberculosis but may also affect the disease course 
and treatment response.
Increasing problem of tuberculosis recogni-
sed in DM patients is due to the fact of global 
increase of DM incidence, in correlation with the 
growing prevalence of obesity. There were 171 
million cases of diabetes diagnosed in 2000, and 
it is calculated that the number will increase to 
366 — 440 million in 2030 [47].
Tuberculosis in transplant recipients 
Development of tuberculosis after transplan-
tation may concern 0.4−15.2% of all transplant 
recipients, i.e. 20 to 74 times more frequently than 
in non-immunocompromised persons from the 
same region [48, 49]. Tuberculosis after transplan-
tation usually develops due to activation of LTBI 
but it can also be caused by the transplantation 
of the organ infected with M. tuberculosis [49]. 
Therefore, every living donor must be precisely 
examined to exclude the presence of the disease. 
In case of any doubt about the quality of organ 
from the dead donor, transplantation should be 
renounced, and if it is not possible, biopsies and 
cultures of the organ should be performed [49].
Every patient on a waiting list to transplan-
tation should be checked for LTBI and especially 
for active tuberculosis [50]. It is much better to 
introduce antituberculous treatment or LTBI 
therapy before transplantation. Antituberculous 
therapy in the transplant recipient may be more 
difficult, because of the interaction between ri-
fampicin and calcineurin inhibitors (cyclosporine 
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and tacrolimus), and between rapamycin and 
glucocorticosteroids [49].
The prognosis of patient with active TB, 
which develops after transplantation, is poor. 
Clinical presentation is often atypical, more than 
half of the patients present extrapulmonary or 
disseminated disease [51].
Drugs that influence immunity to tuberculosis
Oral glucocorticosteroids
It was proved that patients treated with glu-
cocorticosteroids have the increased risk of deve-
loping TB, independent of other factors. The risk, 
according to analysis made in the United Kingdom, 
was 2.8-fold greater for patients taking less than 
15 mg of prednisone daily and 7.7-fold greater for 
those who were treated with a higher dose [52]. It 
depends, however, on the local epidemiology of tu-
berculosis, since it was 1.35% in Spain and 13.8% 
in Philipines [53]. In addition, it was showed that 
patients receiving glucocorticosteroids had the 
diameter TST infiltration smaller than 5 mm [54].
Immunosuppressive drugs
Profound immunosuppression was caused 
by calcineurin inhibitors, cyclosporine and ta-
crolimus, and it was dose dependent [55]. This 
is the reason for the greater risk of activation of 
tuberculosis after transplantation of the lung than 
after kidney transplantation [49, 50].
TNF antagonists
TNF plays a great role in pathogenesis of acu-
te and chronic inflammation such as rheumatic 
arthritis, ankylosis, spondylitis and inflammatory 
bowel disease [56]. Treatment of those sicknesses 
with TNF antagonists is one of the greatest pro-
gress in medicine.
On the other hand, TNF together with IFN 
gamma plays a great role in the immunology of 
tuberculosis [15, 19, 57]. It increases the phago-
cytic activity of macrophages and enhances the 
killing of intracellular bacteria [15, 19, 56, 57]. 
Thus treating with anti-TNF monoclonal antibo-
dies (infliximab, adalimumamb, certolizumab) or 
antibodies for its receptors (etanercept) can pro-
voke activation of LTBI. The reported frequency 
of this complication differs and depends on the 
prevalence of tuberculosis in the local population. 
Reactivation of LTBI occurs more frequently in 
the patients using anti-TNF antibodies than in 
those who use the antagonists to its receptors 
[56]. The disease usually progresses rapidly and 
is frequently disseminated. 
As nearly as all cases of tuberculosis in the 
course of anti-TNF therapy were caused by the 
activation of LTBI, there are many national guide-
lines, including Polish, concerning the algorithm 
of LTBI diagnosing and the use of chemoprophy-
laxis in those infected, before the beginning of 
anti-TNF therapy [58]. This prevents, to a large 
extent, the development of active TB in patients 
treated with anti-TNF drugs, although TB may 
occur in some cases, mostly in the first year of anti
-TNF treatment [59]. Biologic drugs with another 
mechanism of action, used to treat inflammatory 
autoimmune diseases, also increase the risk of 
tuberculosis and require screening towards tuber-
culosis and LTBI prior to the administration [58]. 
The role of age
The most vulnerable to development of dise-
ase after infection with tubercle bacilli are young 
children and old people [60]. In young children, 
the immunologic system is not mature and in old 
persons it is less efficient.
In Poland, BCG vaccination after birth and 
relatively good epidemiological situation, dimi-
nished the problem of active tuberculosis in chil-
dren. In 2014, there were only 1.2/100 000 cases of 
tuberculosis in children from 0 to 14 years of age, 
as opposed to 30.4/100 000 cases of tuberculosis 
diagnosed in the group of persons above 65 years 
of age. Due to some immunosuppression, older 
persons have more disseminated disease and less 
cavities than the younger ones. In addition, due 
to atypical symptoms of tuberculosis and due to 
coexisting diseases, the recognition of active tu-
berculosis in the elderly is more difficult. In 2013, 
the death rate from tuberculosis among persons 
above 65 years old was 3.7/100000 in contrast to 
all the remaining groups of age, in whom it was 
1.4/100 000. 50% of the Polish patients who died 
from tuberculosis in 2013 were over 65 years of 
age [2].
The same trend was observed in other coun-
tries with relatively good epidemiological situ-
ation. In the report from Israel, 75% of persons 
who died from tuberculosis were above 65 years 
of age [61].
The role of cigarettes smoking
It was documented that persons smoking 
cigarettes were more often infected with tubercle 
bacilli [62] and were more often diagnosed with 
active disease [1]. They usually present with more 
advanced lesions [63] and more often suffer from 
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the disease recurrence [64]. Cigarette smokers are 
also a at greater risk of death from tuberculosis [65].
In the experimental work, it was demonstra-
ted that macrophages obtained from healthy non- 
smoking adults had the diminished possibility to 
stop reproduction of bacilli BCG after exposure 
to smoke of cigarettes [66].
Diagnosis of LBTI in immunosuppression
There are many publications that refer to 
the value of various tests to diagnose LTBI in the 
state of immunosuppression, among others, the 
analysis published by TBNET in 2014 [67].
It included 1537 patients with HIV, chronic 
renal failure, rheumatic arthritis, with solid organ 
or stem transplantation and 211 immunocompe-
tent control subjects from 17 centres in 11 Europe-
an countries. All subjects were tested with TST, 
and both IGRAs. According to the study results, 
IGRAs were less influenced by imunosupression 
than TST. However, the indeterminate IGRAs’ 
results were combined with higher immunosup-
presion.
TB developed in 11 of all immunosupressed 
patients in the course of later observation (in 10 
HIV patients and 1 organ transplant recipient). In 
half of them LTBI was not detected by any of the 
three tests. On the contrary, all three tests were 
positive only in 3 of those 11 patients.
Although every test was helpful to predict 
tuberculosis, the authors suggested that TST 
may be superior to IGRAs for the assessment of 
risk of active tuberculosis during the prolonged 
observation of HIV infected patients. Neverthe-
less, they suggested using both IGRA and TST 
in diagnosing LTBI in immunosuppression [67]. 
Similar conclusions were presented by Munoz et 
al. [58] who observed 726 patients treated with 
anti-TNF for 10 years. The suggestion that TST 
should be added to IGRA in diagnosis LTBI in 
immunosuppression was also made by some other 
authors [68, 69].
Before the introduction of IGRA, some experts 
used to diagnose LTBI in immunosupression with 
two step TST [40]. When the first TST was nega-
tive, second application of tuberculin after one 
week, could give positive result (booster effect). 
Nowadays two step TST is not recommended 
because the result of the second test is regarded 
as less specific [59]. 
It should be noted that in the countries, whe-
re entire population was BCG vaccinated (e.g. in 
Poland), it is recommended using solely IGRA 
in screening for LTBI before biologic treatment. 
To exclude LTBI in the immunocompromised 
patients, it is not enough to perform the TST or 
IGRA tests, but it is also important to collect the 
detailed past medical history, especially concer-
ning any tests done before and their results, any 
contact with tuberculosis, and tuberculosis dia-
gnosed in the past. It is also important to perform 
X-ray of the chest. The presence of fibrosis in the 
apex of lungs is considered to be indicative of 
previous tuberculosis infection. According to the 
recommendations, those patients should receive 
chemotherapy without any further TST or IGRA 
testing. Nevertheless, culture of sputum, urine 
and occasionally of BAL, should be done in those 
patients, as in others in whom active tuberculosis 
is suspected. 
According to WHO recommendations, syste-
matic testing for LTBI is not recommended in the 
persons with DM, alcohol abusers and tobacco 
smokers [70].
Chemotherapy for LTBI
It was proved that chemotherapy of LTBI 
prevents to a great extent the development of ac-
tive TB, both in HIV infected persons and those 
treated with anti-TNF drugs [71]. 
According to WHO, there are actually four re-
gimens recommended for LTBI treatment [25, 70]:
Isoniazid alone for 6 or 9 months daily (5mg/
kg daily adults, 10 mg/kg children but not more 
than 300 mg/day)
Rifampin alone for 3 to 4 months (adults and 
children 10 mg/kg — maximum 450 mg for those 
< 45 kg and maximum 600 mg for those > 45 kg)
Isoniazyd plus rifampin for 3−4 months (do-
ses like in scheme with rifampin alone)
Weekly rifapentine plus isoniazid for 3 mon-
ths (rifapentine adults and children 15−30 mg/
kg -900 mg maximum), isoniazid 15 mg/kg (900 
mg maximum).
Summary
Epidemiological situation of TB worldwide 
is influenced by different factors, among oth-
ers: TB strains virulence and drug resistance, 
the amount of population belonging to the risk 
groups, and the organisation of health care. 
Despite the fact that TB incidence rate in many 
counries has been lowered, the achievement of 
elimination phase of disease is difficult due to 
economic factors, immigration and increasing 
number of patients belonging to the risk groups 
of LTBI reactivation.
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